Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 219

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 219
---
  $61.75 |     |  $77.89 |     |  $97.58 |     | $106.54 |     | $115.93 |     | $131.54 |     | $142.20 |
| Free Cash Flow |     | -$41.95 |     | -$13.14 |     | $19.90 |     |  $60.02 |     |  $74.12 |     |  $97.33 |     | $103.79 |     | $114.34 |     | $129.75 |     | $142.55 |

Note: The LNHC Projections through 2034 shown in the table above include projections for ZELSUVMI for the treatment of Molluscum contagiosum infections and are probability-adjusted to reflect the probabilities of technical success determined by LNHC’s management. Interests of Channel Directors and Executive Officers in the Merger In considering the recommendation of the Channel board of directors with respect to the Merger, holders of shares of Channel common stock should be aware that Channel’s executive officers and directors may have interests in the Merger that may be different from, or in addition to, those of Channel stockholders generally. These interests may create potential conflicts of interest. The Channel board of directors and the Special Committee were aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger and to recommend that Channel stockholders vote in favor of the proposals. For purposes of this disclosure, Channel’s executive officers are Francis Knuettel II, Chief Executive Officer and Chief Financial Officer, and Dr. Eric Lang, Chief Medical Officer. For purposes of this disclosure, Channel’s non-employee directors are Todd Davis, Ezra Friedberg, Dr. Richard Malamut and Chia-Lin Simmons. Treatment of Stock Options and Restricted Stock Units As of the closing of the Merger, each stock option to purchase Channel common stock and Channel restricted stock unit award, whether vested or unvested, that is issued and outstanding immediately prior to the closing of the Merger, including those held by any executive officer or non-employee director of Channel, shall continue to remain an issued and outstanding stock option or restricted stock unit, as applicable, and continue to be subject to the same terms and conditions as of immediately prior to the closing of the Merger. As of May 2, 2025, Mr. Knuettel held unvested stock options to purchase